MGC Pharmaceuticals (ASX:MXC) has completed a pre-clinical study on CimetrA™, which examined the mechanism underlying its anti-inflammatory effect on human Peripheral Blood Mononuclear Cells (PBMC).
The study demonstrated the inhibitory effect of CimetrA™ on the mRNA expression and, as a result, on the secretion of IL-32 proteins and the subsequent suppression of inflammation and inflammatory cytokines.
Additional findings showed an increase in intracellular Heme-Oxygenase-1 (HO-1) levels, an enzyme which facilitates the breakdown of metabolites in the cell, enhancing the antioxidant activity and providing protection against oxidative stress, which can cause inflammation.
The results of this study will form part of the US Food and Drug Administration (FDA) application to register CimetrA™ as an Investigational New Drug (IND) and will enable the Company to expand the trials in the future to show its efficacy against further indications.